Browsing by Author Hughes, Michael D.
Showing results 1 to 2 of 2
Issue Date | Title | Author(s) |
2022-06 | Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial | Avihingsanon, Anchalee; Hughes, Michael D.; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn; Mugyenyi, Peter |
2022 | Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial | Avihingsanon1, Anchalee; Hughes, Michael D.; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn |